critique

**Counter-Evidence:**
PMID 29669042 demonstrates that P-glycoprotein inhibition dramatically increases brain penetration of fentanyl by 2.9-fold, but this led to severe respiratory toxicity and death, highlighting the protective role of efflux transporters.

**Falsification Experiments:**
1. Monitor toxin accumulation (heavy metals, xenobiotics) in brain during chronic efflux inhibition
2. Assess drug interaction profiles with commonly used medications
3. Evaluate compensatory upregulation of alternative efflux systems

**Revised Confidence: 0.45** (reduced due to significant safety concerns from protective transporter inhibition)

---

## **Summary of Revised Confidence Scores:**

1. **Dual-Targeting BBB Shuttle-Amyloid Antibodies**: 0.8 → **0.6**
2. **LRP1-Mediated Trojan Horse Delivery**: 0.75 → **0.5** 
3. **Cell-Penetrating Peptide Conjugated Nanobodies**: 0.7 → **0.45**
4. **Focused Ultrasound-Enhanced Antibody Delivery**: 0.85 → **0.7**
5. **Engineered Exosome-Encapsulated Antibody Fragments**: 0.65 → **0.4**
6. **Intranasal Delivery of BBB-Penetrating Antibody Conjugates**: 0.6 → **0.35**
7. **Bi-directional Transcytosis Inhibition Strategy**: 0.75 → **0.45**

## **Overall Assessment:**
All hypotheses suffer from **overconfidence in the amyloid hypothesis itself** and underestimation of technical/safety challenges. The most promising approach remains **Hypothesis 4 (Focused Ultrasound)** due to its clinical feasibility and reversible nature, though safety concerns warrant careful monitoring. The least promising are **Hypotheses 6 and 5** due to fundamental physical/technical limitations.

**Key Missing Consideration:** None of these hypotheses address whether enhanced amyloid antibody delivery will actually improve clinical outcomes, given the repeated failures of amyloid-targeting therapies even with adequate drug exposure.